Want to see KR:003220 full AI Analyst Report?
Top Page
Daewon Pharmaceutical Co., Ltd
(003220)
Select Model
Select Model
Rating:50Neutral
Price Target:
$7,730.00
Action:N/A
Date:10/28/26
The score is driven primarily by mixed financial performance—strong revenue growth but weakened operating profitability and inconsistent free cash flow. Technical indicators are also unfavorable with the stock trading below major moving averages and a negative MACD. Valuation adds pressure due to a high P/E, only partly offset by the dividend yield.
Positive Factors
Strong Revenue Growth
The company is experiencing substantial top-line acceleration, indicating stronger sales across its pharmaceutical portfolio and distribution channels. If maintained, this growth can expand operating scale, support broader market reach, and provide a larger revenue base for restoring profitability over the next several quarters.
Negative Factors
Negative Operating Profitability
Negative EBIT indicates that current operating costs exceed the profit generated by the business despite rapid revenue growth. This weakens earnings quality and shows that sales expansion is not yet translating into durable operating leverage, making margin recovery a central execution requirement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The company is experiencing substantial top-line acceleration, indicating stronger sales across its pharmaceutical portfolio and distribution channels. If maintained, this growth can expand operating scale, support broader market reach, and provide a larger revenue base for restoring profitability over the next several quarters.
Read all positive factors
Daewon Pharmaceutical Co., Ltd (003220) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩169.19B
Dividend Yield3.22%
Average Volume (3M)39.50K
Price to Earnings (P/E)63.8
Beta (1Y)-0.04
Revenue Growth1.83%
EPS Growth-67.89%
CountryKR
Employees1,349
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)122.58
Shares Outstanding22,427,584
10 Day Avg. Volume45,555
30 Day Avg. Volume39,499
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)0.96
Price to Sales (P/S)0.42
P/FCF Ratio18.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)450
Revenue Forecast (FY)₩630.50B
Daewon Pharmaceutical Co., Ltd Business Overview & Revenue Model
Company Description
Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and ...
Daewon Pharmaceutical Co., Ltd Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 614.84B | 605.64B | 598.16B | 526.95B | 478.88B | 354.18B |
| Gross Profit | 275.92B | 266.09B | 287.33B | 254.23B | 237.94B | 176.47B |
| EBITDA | -40.46B | 27.23B | 45.56B | 48.01B | 61.77B | 37.11B |
| Net Income | 2.63B | -1.38B | 14.21B | 23.92B | 31.94B | 6.99B |
Balance Sheet | ||||||
| Total Assets | 573.33B | 613.65B | 583.39B | 508.00B | 453.55B | 429.58B |
| Cash, Cash Equivalents and Short-Term Investments | 66.18B | 76.48B | 46.11B | 30.03B | 47.01B | 54.82B |
| Total Debt | 189.15B | 187.08B | 187.24B | 146.05B | 116.48B | 123.97B |
| Total Liabilities | 297.60B | 335.21B | 298.81B | 243.73B | 204.78B | 211.18B |
| Stockholders Equity | 267.68B | 265.92B | 275.28B | 266.20B | 250.95B | 219.30B |
Cash Flow | ||||||
| Free Cash Flow | 2.02B | 13.78B | -23.55B | 31.12B | 19.96B | 10.71B |
| Operating Cash Flow | 25.15B | 43.58B | 30.04B | 51.73B | 33.33B | 22.41B |
| Investing Cash Flow | -1.70B | -12.99B | -42.98B | -68.27B | -27.69B | -41.62B |
| Financing Cash Flow | -2.28B | 6.60B | -297.81M | 19.51B | -20.41B | 48.53B |
Daewon Pharmaceutical Co., Ltd Technical Analysis
Negative
―
Price Trends
7888.80
Negative
8075.50
Negative
9384.60
Negative
Market Momentum
-42.90
Positive
46.74
Neutral
23.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003220, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 7863.00, equal to the 50-day MA of 7888.80, and equal to the 200-day MA of 9384.60, indicating a bearish trend. The MACD of -42.90 indicates Positive momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 23.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003220.
Daewon Pharmaceutical Co., Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,032.16
-39.34%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,440.00
-15.62%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
177.39
4.97%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-9,625.21
-21.62%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-9,511.57
-42.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.